LON:NIPT - Premaitha Health Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Premaitha Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NIPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NIPT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
This price target is based on 0 analysts offering 12 month price targets for Premaitha Health in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.

N/A

The current consensus among 0 investment analysts is to n/a stock in Premaitha Health. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2018FinnCapReiterated RatingCorporate
i
9/19/2018FinnCapReiterated RatingCorporate
i
5/15/2018FinnCapReiterated RatingCorporate
i
3/26/2018FinnCapReiterated RatingCorporate
i
12/11/2017FinnCapReiterated RatingCorporate
i
11/27/2017FinnCapReiterated RatingCorporate
i
11/21/2017FinnCapReiterated RatingCorporate
i
9/29/2017FinnCapReiterated RatingCorporate
i
8/24/2017FinnCapReiterated RatingCorporate
i
7/12/2017FinnCapReiterated RatingCorporate
i
6/16/2017FinnCapReiterated RatingCorporate
i
5/30/2017FinnCapReiterated RatingCorporate
i
5/16/2017FinnCapReiterated RatingCorporate
i
2/26/2017FinnCapReiterated RatingCorporateGBX 18
i
2/20/2017FinnCapReiterated RatingCorporateGBX 18
i
2/13/2017FinnCapReiterated RatingCorporateGBX 18
i
2/7/2017FinnCapReiterated RatingCorporateGBX 18
i
12/21/2016FinnCapLower Price TargetCorporateGBX 20 ➝ GBX 18
i
11/29/2016FinnCapReiterated RatingCorporateGBX 20
i
11/21/2016FinnCapReiterated RatingCorporateGBX 20
i
10/27/2016FinnCapReiterated RatingCorporateGBX 20
i
9/30/2016FinnCapReiterated RatingCorporateGBX 20
i
8/30/2016FinnCapReiterated RatingCorporateGBX 20
i
7/4/2016Panmure GordonReiterated RatingBuyGBX 24
i
7/4/2016FinnCapReiterated RatingCorporateGBX 20
i
(Data available from 6/14/2016 forward)
Premaitha Health logo
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal screening test for pregnant women to estimate Down's syndrome, Edward's syndrome, and Patau's syndrome. The IONA test is a diagnostic system that enables clinical laboratory customers to perform the test in their own facilities. The company is headquartered in Manchester, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: GBX 9.10
8.90
9.10

52 Week Range

Now: N/A

Volume

1,571,557 shs

Average Volume

1,348,942 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Premaitha Health?

The following sell-side analysts have issued reports on Premaitha Health in the last twelve months:
View the latest analyst ratings for NIPT.

What is the current price target for Premaitha Health?

0 Wall Street analysts have set twelve-month price targets for Premaitha Health in the last year. has the lowest price target set, forecasting a price of £100,000 for Premaitha Health in the next year.
View the latest price targets for NIPT.

What is the current consensus analyst rating for Premaitha Health?

Premaitha Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NIPT.

What other companies compete with Premaitha Health?

How do I contact Premaitha Health's investor relations team?

Premaitha Health's physical mailing address is Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom. The company's listed phone number is +44-161-6676865. The official website for Premaitha Health is www.premaitha.com.